Aquestive Therapeutics (AQST) Revenue (2017 - 2026)

Aquestive Therapeutics' Revenue history runs 10 years deep, the most recent figure standing at $14.4 million for Q1 2026.

• On a quarterly basis, Revenue rose 65.67% year-over-year to $14.4 million in Q1 2026; TTM through Mar 2026 was $6.7 million, a 87.71% decrease from a year earlier, with the FY2025 full-year figure at $938000.0, down 98.37% from the prior year.
• Revenue grew to $14.4 million in Q1 2026 per AQST's latest filing, from -$30.6 million in the prior quarter.
• Across five years, Revenue topped out at $20.1 million in Q2 2024 and bottomed at -$30.6 million in Q4 2025.
• The 5-year median for Revenue is $12.1 million (2024), against an average of $9.8 million.
• Across the five-year window, Revenue soared 300.0% in 2022 and slumped 357.79% in 2025, its largest moves.
• Year by year, Revenue stood at $10.7 million in 2022, then increased by 23.63% to $13.2 million in 2023, then fell by 10.14% to $11.9 million in 2024, then tumbled by 357.79% to -$30.6 million in 2025, then jumped by 147.22% to $14.4 million in 2026.
• Per Business Quant, the three latest AQST Revenue figures stand at $14.4 million (Q1 2026), -$30.6 million (Q4 2025), and $12.8 million (Q3 2025).